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Abstract
The most common, X-linked, form of chronic granulomatous disease (CGD) is caused by mutations in the CYBB gene
located at Xp21.1. The product of this gene is the large subunit of flavocytochrome b558, gp91phox, which forms the catalytic
core of the antimicrobial superoxide-generating enzyme, NADPH oxidase. In the overwhelming majority of cases, mutations
are family-specific and occur in the exonic regions of the gene, or more rarely at the intron/exon borders. Alternatively, they
are large (often multi-gene) deletions. In addition, four mutations have been found in the promoter region. In contrast, very
few intronic mutations have been reported. Here we describe an intronic mutation that causes X-linked CGD. A single
nucleotide substitution in the middle of intron V creates a novel 5P splice site and results in multiple abnormal mRNA
products. ß 2001 Elsevier Science B.V. All rights reserved.
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1. Introduction
Chronic granulomatous disease (CGD) is a rare
inherited disorder of the innate immune system.
The disease is characterized by a severe susceptibility
to infection due to the failure of phagocytic leuko-
cytes (neutrophils, eosinophils, macrophages and
monocytes) to produce microbicidal reactive oxygen
species [1]. The source of these radicals is superoxide
(O32 ) generated by NADPH oxidase, a multicompo-
nent enzyme complex. Defects in any of four com-
ponents of NADPH oxidase (p47phox, p67phox,
p22phox or gp91phox encoded by the NCF1, NCF2,
CYBA and CYBB genes, respectively) can give rise
to CGD [1,2]. Recently, a CGD-like syndrome has
been described that is caused by a mutation in a ¢fth
essential component, Rac2 [3,4]. With the exception
of gp91phox, the a¡ected genes in CGD are autoso-
mal, and we have recently tabulated all the known
mutations in these genes [5].
The most common form of CGD is X-linked and
is caused by defects in the CYBB gene that codes for
the large subunit of £avocytochrome b558, gp91phox,
the heme and £avin-containing core of NADPH ox-
idase. The 30 kb CYBB gene consists of 13 exons and
is located at Xp21.1. Our studies and those of others
have revealed a broad distribution of family-speci¢c
defects in patients with X-linked CGD. The known
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mutations have been recently tabulated [6]. These
include small and large deletions, insertions, non-
sense and missense mutations, splice site defects
and, rarely, mutations in the 5P regulatory region.
To date, only two patients have been described
that have gp91phox de¢ciency arising from intronic
defects within CYBB (aside from large deletions
and splice site mutations). One was the result of
the insertion of a LINE-1 element in intron V, fol-
lowed by an internal rearrangement that generated
new splice sites within the intron [7]. In the second
case, we described a patient in whom a single nucle-
otide substitution in the middle of intron VI gener-
ated a new 3P splice site that caused a 94 bp ‘pseu-
doexon’ to be inserted into the mRNA [8]. In the
course of our continuing studies of mutations caus-
ing CGD, we have found and characterized another
patient who has a defect arising from an intronic
mutation remote from the neighboring exons. This
individual had a single nucleotide substitution in in-
tron V that generated a new 5P splice site and re-
sulted in multiple mRNA products, one with 110
nucleotides spliced in between exons 5 and 6 and
another product with 61 nucleotides spliced in.
2. Materials and methods
2.1. Patient
The patient is a 9-month-old boy with neutrophils
that failed to reduce NBT and a history of otitis
media. His mother has had a life-long history of
chronic skin abscesses and was originally diagnosed
as having autosomal recessive CGD as a child. On
examination as an adult, she was found to have 15%
positive cells in the NBT test and 10% positive by
dihydrorhodamine £ow cytometry, suggestive of a
carrier of X-linked CGD with skewed X-inactivation.
Blood samples were obtained following the proce-
dures approved by the Scripps Research Institute’s
Human Subjects Committee.
2.2. Single strand conformation polymorphism
(SSCP) analysis and sequencing of exons
Genomic DNA was extracted from whole blood
using the Puregene Blood Kit (Gentra Systems,
MN). DNA was analyzed by SSCP as described pre-
viously [8] using 18^27 bp oligonucleotide primers
and 500 ng genomic DNA. Ampli¢cation products
were run on 20% TBE gels in a Thermo£ow unit
(Invitrogen (formerly Novex), Carlsbad, CA). SSCP
analysis was performed on the 5P £anking region
from 171 bp from the start of the coding region,
through all 13 exons, and 26 bp of the 3P untrans-
lated region. Other DNA sequencing was performed
as described previously and as described below [9,10].
2.3. Nuclear run-on assays
Transcription of the CYBB gene encoding gp91phox
in B cell lines from the patient and a normal control
was assessed by nuclear run-on transcription assays
with minor modi¢cations of previously published
procedures [11]. Epstein^Barr virus (EBV)-trans-
formed B cells were derived from peripheral blood
and cultured in RPMI 1640 medium (supplemented
with 10% heat inactivated fetal bovine serum, 2 mM
L-glutamine, 100 U/ml penicillin, and 100 Wg/ml
streptomycin) as previously described [12]. Nuclei
were isolated by cell lysis in 0.05% Nonidet P-40
and immediately incubated for 30 min at 30‡C in
a reaction mixture containing [32P]UTP (250 WCi,
3000 Ci/mmol) in bu¡er modi¢ed from Greenberg
et al. [11] by addition of 0.8 mM MnCl2. Newly syn-
thesized RNA was extracted by the guanidine HCl
method [13]. Equal amounts of incorporated label
from each sample (1^2U107 cpm) were then hybrid-
ized to saturating amounts of cDNA probes, immo-
bilized on ¢lters by slot blotting. The probes used in
these experiments included cDNAs for the genes en-
coding gp91phox, p22phox, and p47phox, a hybridization
negative control (plasmid without insert), and the
constitutively expressed gene for KK1-tubulin [14].
Relative rates of transcription were calculated by
computer analysis of phosphorimager data, with nor-
malization to negative control slots for each ¢lter.
2.4. Sequencing of the 3P region
Only 14 bp of sequence 3P of the polyadenylation
signal were known (GenBank accession No.
NM_000397.1) so an additional 3P sequence was
needed to design a primer in order to amplify this
region. The necessary sequence was obtained from
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PAC clone 7287 (which contains the entire CYBB
gene) by performing a PCR reaction using a SP6
primer modi¢ed to increase speci¢city (SP6m), and
a primer 63 bp 5P of the poly(A) signal (poly(A-F))
employing the Expand Long Template PCR system
(Roche, Indianapolis, IN) under the following con-
ditions: an initial denaturation at 95‡C for 3 min
followed by 10 cycles of 95‡C for 30 s, 60‡C for
30 s, and 68‡C for 4 min, then 20 cycles of 95‡C
for 30 s, 60‡C for 30 s, and 68‡C for 4 min with a
cycle elongation of 20 s, followed by a 7 min exten-
sion at 68‡C. The resulting 3 kb product was parti-
ally sequenced and an additional 343 bp of sequence
3P of the poly(A) region was obtained. A primer
(poly(A-R)) was designed from this sequence and
used to amplify a 281 bp region containing the
poly(A) signal. The remaining 2385 bp of the
3PUTR was ampli¢ed with a primer 50 bp 3P of
exon 13 (3PUTR1) and a reverse primer 106 bp 5P
of the poly(A) signal (poly(A-R3)) using Expand
Long Template as follows: an initial denaturation
at 95‡C for 3 min followed by 10 cycles of 94‡C
for 15 s, 60‡C for 30 s, and 68‡C for 2 min, then
20 cycles of 94‡C for 15 s, 60‡C for 30 s, and 68‡C
for 2 min with a cycle elongation of 20 s, followed by
a 7 min extension at 68‡C, with sequencing in
11 steps.
2.5. mRNA analysis
mRNA was analyzed using RNA isolated from
whole blood using the RNeasy Kit (Qiagen, Valen-
cia, CA). cDNA was prepared using RT-PCR
(cDNA kit, Life Technologies, Rockville, MD) using
a forward primer from exon 1 and a reverse primer
from exon 13. The cDNA products were visualized
on agarose gels using ethidium bromide.
2.6. Sequencing of intron V
Sequencing of intron V was achieved by ¢rst am-
plifying the region from exon 5 to 6 by PCR using
Expand High Fidelity under the following condi-
tions: an initial denaturation at 94‡C for 3 min, fol-
lowed by 10 cycles of 94‡C for 15 s, 63‡C for 30 s,
and 68‡C for 1 min and 20 s, then 20 cycles of 94‡C
for 15 s, 63‡C for 30 s, and 68‡C for 1 min and 20 s
with a cycle elongation of 20 s. This was followed by
a 7 min extension at 72‡C. Stepwise sequencing of
the entire 2.1 kb of intron V was performed in eight
steps. The primers used are shown in Table 1.
3. Results and discussion
3.1. Mutation analysis of the patient’s exonic
sequences
SSCP analysis of genomic DNA did not reveal any
abnormalities in the 5P £anking region (from 171 bp
upstream from the coding region) in any of the
13 exons in the 26 bp 3P of exon 13). Although our
previous experience has shown that almost 95% of
mutations can be detected in this way [9], we initially
sequenced all the exonic regions of DNA as de-
scribed in Section 2. In keeping with the SSCP re-
sults, all the exonic sequence was found to be normal
(including the intron/exon borders). An additional
222 bp were sequenced upstream, but no abnormal-
ities were found.
3.2. CYBB gene transcription is normal in the patient
To determine if long-range (i.e. beyond 393 bp
upstream from CYBB) promoter or regulatory re-
gion defects were responsible for the lack of
gp91phox, transcription rates were checked by per-
forming nuclear run-on assays as described in Sec-
tion 2. As shown in Table 2 there was no defect in
transcription of the gp91phox gene in the patient’s B
cells. Transcription rates for all the oxidase compo-
nents were similar in the two cell lines, with margin-
ally higher expression in the patient’s, as previously
observed in other CGD cell lines representing post-
transcriptional molecular defects (C. Whitney and
P.E. Newburger, unpublished data).
3.3. The 3P untranslated region of the patient’s
CYBB gene is normal
To determine if there was a defect in the 3PUTR
that might lead to unstable mRNA and result in loss
of gp91phox synthesis, we sought to sequence the re-
gion 3P of the CYBB gene. As described in Section 2,
initial attempts using standard SP6 and T7 primers
were unsuccessful as the signal was too weak to iden-
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tify the correct product. We successfully designed
modi¢ed primers (SP6m and T7m, Table 1) that im-
proved primer speci¢city and used them in combina-
tion with the poly(A-F) primer in ampli¢cation reac-
tions. Depending on the orientation of the CYBB
gene in the PAC vector, it was predicted that one
of these PCR pairs would yield a fragment contain-
ing the region of interest. A 3 kb fragment was suc-
cessfully ampli¢ed by PCR using the SP6m/poly-
(A-F) pair. This fragment was used to obtain 2434
bp of sequence 3P of exon 13 in 11 steps as described
in Section 2. The sequence in the patient was identi-
cal to a normal control (including the polyadenyla-
tion signal) except that a tCg transversion was
found at the +559 bp position. However, the pa-
tient’s mother, who is a carrier of the disease and
has a population of neutrophils with functional
NADPH oxidase, was homozygous for this change,
indicating that it is a benign polymorphism.
3.4. There is an intronic defect in the patient
For the initial analysis of exons, primers were
chosen to sequence 14^22 bp into the ends of each
intron in order to detect defects that could lead to
aberrant splicing, but we were unable to ¢nd any
such abnormalities in the patient’s DNA. In order
to examine the possibility that mutations deeper
within the introns might cause the generation of
new splice sites, the mRNA from the patient was
examined. Ampli¢cation by RT-PCR of his mRNA
from exons 1^13 gave only a faint smear. The quality
of the mRNA sample was checked by PCR ampli¢-
cation of two unrelated genes (glucose-6-phosphate
dehydrogenase and p67phox) and normal products
were obtained in both cases. RT-PCR was repeated
in CYBB from exons 2^8, 3^8, 4^8 and 5^8. In the
former cases only non-speci¢c products were ob-
tained; in the case of exons 5^8, two products were
obtained but of the wrong size (Table 2). An addi-
tional attempt to amplify the cDNA from exons 1^13
was made using 5% DMSO in the reaction mix in
order to increase primer speci¢city [15]. In the pa-
tient a rather di¡use cDNA product of slightly larger
Table 2
Transcription rates of phox genes in B lymphocytes
Transcript CGD normal ratio
gp91phox 53 749 32 959 1.63
p22phox 103 989 87 459 1.19
p47phox 181 473 149 395 1.21
Tubulin 30 031 34 875 0.86
Transcription rates of genes encoding gp91-phox, p22-phox, and
p47-phox in EBV-transformed B lymphocytes. Representative
nuclear run-on assay showing the transcription rates, in arbi-
trary phosphorimager density units, of the indicated genes in
nuclei from normal and CGD EBV-transformed B lymphocytes.
The K-tubulin gene served as a constitutive control.Table 1






































The following primers were used for PCR and sequence analy-
sis as described in Section 2. Additional primers for SSCP and
sequencing are given in [9].
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size than the product from the control sample was
observed, after analysis by agarose gel electrophore-
sis (Fig. 1).
To further analyze this anomaly, additional prim-
ers were designed in order to perform RT-PCRs in
di¡erent areas of the gene (Table 1). Using this strat-
egy, we were able to localize the defect to either in-
tron IV or intron V, as normal product (although of
diminished abundance) could be obtained using
primers between exons 1^4 and 6^13 (Table 3). In-
tron V was ampli¢ed from genomic DNA by per-
forming a PCR from exon 5 to 6 (2.1 kb) as de-
scribed in Section 2. A single nucleotide
substitution at +978 bp (gCt) generates a putative
5P splice site (ggaagaCgtaaga) (Fig. 2). As expected,
the patient’s mother was found to be a carrier of this
mutation (Fig. 2). We hypothesized that as a conse-
quence of the generation of this 5P donor site, nearby
cryptic 3P acceptor site(s) might be activated. Ampli-
Fig. 2. Generation of a putative 5P splice site by a gCt transi-
tion at +978 nt in intron V. Sequencing of intron V was per-
formed as described in Section 2. Upper trace, normal control;
middle trace, the patient’s mother; lower trace, patient. The ar-
row is below nucleotide +978 in intron V; normal control, ho-
mozygous g; patient’s mother, heterozygous g/t ; patient, hemi-
zygous t.
Table 3
RT-PCR products from the patient’s cDNA
Primers Product Primers Product
1F, 3R ++ 5F, 8R a
1F, 4R + 6F, 13R +++
1F, 5R 3 7F, 13R +++
1F, 6R 3 9F, 13R ++++
3F, 8R 3 11F, 13R ++++
4F, 8R 3
cDNA was ampli¢ed using the primers indicated [9] and the
products visualized by ethidium bromide staining and scored by
eye.
aTwo products, both of abnormal size.
Fig. 1. Analysis of mRNA from the patient and a normal con-
trol by RT-PCR. RT-PCR was used to amplify mRNA from
patient and control samples in the presence of 5% DMSO, as
discussed in Section 3. The normal cDNA product is 1666 bp,
the patient has two products of 1727 bp and 1776 bp.
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¢cation of the cDNA using primers from exons 5^8
followed by direct sequencing of the product using
primer cDNA5F allowed us to identify two major
mRNA species with either 61 or 110 nucleotides
spliced in. Examination of the genomic sequence sur-
rounding the mutation con¢rmed the presence of two
cryptic 3P acceptor sites 61 and 110 nucleotides up-
stream from the 5P site. As a result, two major
mRNA species are formed as shown in Fig. 3 with
either 61 or 110 nucleotides spliced in between exons
5 and 6. Scoring the splice sites by the method of
Shapiro and Senapathy [16] gave scores of 72 for the
distal 3P site (cagcatttctctag) and 88 for the proximal
3P site (ttctatcccagcag). The newly created 5P donor
site has a score of 86.5. Surprisingly, analysis of the
5P sequence revealed the presence of several cryptic
splice sites with scores above 73 that are apparently
not used (or used at low frequency), presumably due
to structural restraints or because there is no suitable
adenosine for lariat formation. According to Talerico
and Burget [17], normally silent 3P splice sites are
recognized with high e⁄ciency when point mutations
create a 5P splice site within adjacent downstream
intron sequences. In an attempt to identify other
splice forms, exons 4^8 were ampli¢ed using primer
cDNA4F. In addition to the two major products
described above, a number of minor species were
seen with sequences diverging after exon 4. The pres-
ence of these low-abundance products is probably
the cause of the di¡use appearance of the patient’s
mRNA band in Fig. 1.
This study illustrates the rare event wherein an
apparently insigni¢cant point mutation in ‘junk
DNA’ can result in a catastrophic lesion leading to
disease.
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